Bioatla Inc (BCAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.89M
Last updated: Nov 13, 2026 at 4:00 PM ET
Bioatla Inc (BCAB) Earnings: Report Dates and Results
Bioatla (BCAB) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Bioatla reported EPS of $0.14, above the -$8.50 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
BCAB has an expected report date of Mar 29, 2027.
BCAB Earnings Call
The latest BCAB earnings call transcript on file is labeled 2025Q3.
Read the 2025Q3 transcriptEarnings History
Of the 21 quarters below that had an estimate, BCAB beat 13 and missed 8. The widest gap in the table came in the quarter ended Jun 30, 2026, when EPS landed 101.65% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | $0.14 | -$8.50 | N/A | +101.65% | Beat | N/A | N/A | N/A | Aug 6, 2026 | $6.50M |
| Mar 31, 2026 | -$4.22 | -$0.20 | -$0.20 - -$0.20 | N/A | N/A | N/A | 1 | 1 up, 0 down | May 15, 2026 | N/A |
| Dec 31, 2025 | Not reported | -$0.30 | N/A | N/A | Not reported | N/A | N/A | N/A | Mar 31, 2026 | $2.00M |
| Sep 30, 2025 | -$13.50 | -$14.83 | -$16.00 - -$13.00 | +8.97% | Beat | N/A | 3 | 1 up, 2 down | Nov 13, 2025 | N/A |
| Jun 30, 2025 | -$0.31 | -$0.29 | -$0.36 - -$0.23 | -6.90% | Miss | N/A | 3 | 1 up, 1 down | Aug 7, 2025 | N/A |
| Mar 31, 2025 | -$13.00 | -$14.67 | -$17.00 - -$13.00 | +11.38% | Beat | N/A | 3 | 1 up, 0 down | May 6, 2025 | N/A |
| Dec 31, 2024 | -$0.30 | -$0.38 | -$0.47 - -$0.33 | +21.05% | Beat | N/A | 3 | 1 up, 0 down | Mar 27, 2025 | N/A |
| Sep 30, 2024 | -$11.00 | -$18.50 | -$19.00 - -$17.00 | +40.54% | Beat | N/A | 3 | 0 up, 0 down | Nov 7, 2024 | $11.00M |
| Jun 30, 2024 | -$22.00 | -$23.00 | -$25.50 - -$17.50 | +4.35% | Beat | N/A | 5 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$24.00 | -$27.12 | -$30.00 - -$22.00 | +11.50% | Beat | N/A | 5 | 0 up, 0 down | May 14, 2024 | N/A |
| Dec 31, 2023 | -$0.56 | -$0.79 | -$1.00 - -$0.71 | +29.04% | Beat | N/A | 4 | 0 up, 0 down | Mar 26, 2024 | $1.71M |
| Sep 30, 2023 | -$35.00 | -$39.87 | -$43.50 - -$35.50 | +12.21% | Beat | N/A | 5 | 0 up, 0 down | Nov 7, 2023 | N/A |
| Jun 30, 2023 | -$37.50 | -$32.10 | -$34.50 - -$29.50 | -16.82% | Miss | N/A | 6 | 0 up, 0 down | Aug 1, 2023 | N/A |
| Mar 31, 2023 | -$29.00 | -$31.20 | -$32.50 - -$30.50 | +7.05% | Beat | N/A | 6 | 0 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$0.63 | -$0.70 | -$0.87 - -$0.45 | +10.00% | Beat | N/A | 7 | 0 up, 0 down | Mar 23, 2023 | N/A |
| Sep 30, 2022 | -$34.50 | -$40.80 | -$45.00 - -$36.50 | +15.44% | Beat | N/A | 7 | 0 up, 0 down | Nov 4, 2022 | N/A |
| Jun 30, 2022 | -$38.50 | -$33.83 | -$35.50 - -$31.00 | -13.80% | Miss | N/A | 6 | 0 up, 0 down | Aug 9, 2022 | N/A |
| Mar 31, 2022 | -$32.50 | -$31.50 | -$37.00 - -$26.00 | -3.17% | Miss | N/A | 5 | 0 up, 0 down | May 5, 2022 | N/A |
| Dec 31, 2021 | -$0.62 | -$0.63 | -$0.93 - -$0.36 | +1.59% | Beat | N/A | 5 | N/A | Mar 1, 2022 | $250000 |
| Sep 30, 2021 | -$34.85 | -$22.83 | -$49.50 - -$10.50 | -52.65% | Miss | N/A | 5 | N/A | Nov 15, 2021 | N/A |
| Jun 30, 2021 | -$45.00 | -$28.00 | -$32.50 - -$26.00 | -60.71% | Miss | N/A | 5 | N/A | Aug 13, 2021 | $250000 |
| Mar 31, 2021 | -$28.00 | -$23.00 | N/A | -21.74% | Miss | N/A | 4 | N/A | May 12, 2021 | N/A |
| Dec 31, 2020 | -$1.50 | -$0.78 | -$0.88 - -$0.66 | -92.31% | Miss | N/A | 3 | N/A | Mar 25, 2021 | $150000 |
| Sep 30, 2020 | -$0.83 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 17, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$26.81, after -$57.30 the year before. It was -$2.33 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$26.81 | N/A |
| Dec 31, 2024 | -$57.30 | N/A |
| Dec 31, 2023 | -$102.06 | N/A |
| Dec 31, 2022 | -$106.13 | N/A |
| Dec 31, 2021 | -$108.47 | N/A |
| Dec 31, 2020 | -$2.33 | N/A |
Earnings Calls
The 5 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 2,500 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q3 | Sep 30, 2025 | 2,522 | 7 | |
| 2025Q2 | Jun 30, 2025 | 2,112 | 6 | |
| 2025Q1 | Mar 31, 2025 | 3,722 | 8 | |
| 2024Q3 | Sep 30, 2024 | 3,983 | 9 | |
| 2024Q2 | Jun 30, 2024 | 3,361 | 8 |
2025Q3 Earnings Call
Opening remarks
Julie Miller LifeSci Advisors Thank you, operator, and good afternoon, everyone. With me today on the phone from BioAtla, Inc. are Dr. Jay M. Short, Chairman, CEO, and Co-founder; Dr. Eric L. Sievers, Chief Medical Officer; Sheri Lydick, Chief Commercial Officer; and Richard A. Waldron, Chief Financial Officer. Earlier this afternoon, BioAtla, Inc. released financial results and a business update for the quarter ended 09/30/2025. A copy of the press release is available on the company's website. Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtla, Inc.'s business plans and prospects, potential selective licensing, collaborations, and other strategic partnerships. The potential for our clinical trials to yield registrational results, conduct progress, timing of our research and development programs and clinical trials, expectations with respect to enrollment and dosing in our clinical trials, the anticipated clinical benefits, safety, efficacy, and market potential of our product candidates, plans and expectations regarding future data updates, clinical trials, regulatory meetings, and regulatory submissions. The potential regulatory approval path for our product candidates, expectations about the sufficiency of our cash and cash equivalents, and expected R&D and G&A expenses. These statements are based on current expectations and are subject to various risks and uncertainties that can cause actual results to differ materially from those expressed or implied. These risks and uncertainties are described in our filings made with the SEC, including the most recent quarterly report on Form 10-Q and other subsequent filings. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of today, 11/13/2025. And BioAtla, Inc. disclaims any obligation to update or revise such statements to reflect new information, future events, or circumstances except as required by law. With that, I'd like to turn the call over to Jay M. Short. Jay?
Jay M. Short CEO Thank you, Julie. And thanks to everyone for joining us for our third quarter 2025 BioAtla, Inc. earnings call. First and foremost, it is important to update that we are in advanced stages to finalize a strategic transaction with a potential partner by year-end. Further, in September, I'm pleased to report that we achieved FDA alignment on the phase three OSV registrational trial design including dosing regimen, comparator arm, and approval endpoints for the treatment of second-line plus oropharyngeal squamous cell carcinoma or OPSCC. OPSCC represents a sizable and steadily growing patient population poorly served by EGFR inhibitors and other standard of care regimens. Importantly, this randomized phase three trial will evaluate dual primary endpoints of overall response rate and overall survival. And this dual endpoint design provides the opportunity for achieving accelerated approval followed by full approval.
Frequently Asked Questions About BCAB
When is Bioatla's next earnings date?
Bioatla's next earnings report is expected for Mar 29, 2027.
Did BCAB beat earnings estimates last quarter?
Yes. Bioatla reported EPS of $0.14 for the quarter ended Jun 30, 2026, above the -$8.50 estimate, a 101.65% surprise.
How often does BCAB beat earnings estimates?
Bioatla beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +24.07%.
BCAB pages: Overview, Earnings, Financials, Competitors